Current and future therapeutic trends of Ondansetron practice


Changing trend of Anti-emetic drugs practice in the management of patient with Prevention of nausea-vomiting associated with chemotherapy, Prevention of nausea & vomiting associated with radiotherapy, Prevention of post-operative nausea & vomiting, Nausea-vomiting in gastroenteritis and Nausea vomiting in pregnancy, is the market reality. In the year 2016, an around 29% doctors used to prefer Ondansetron whenever indication for a Anti-emetic drugs came-across in clinical management. Presently, an approx 30% doctors prefer Ondansetron for clinical indication; is expected to increase further 39% over the forecast period of 2020 - 2022. A simultaneous declined preference is expected in other Anti-emetic drugs. In addition, an increase incidence of related diseases are presumed to be the key contributing factors providing a fillip this generic vertical. Increased awareness, availability of drugs by the key companies, rising demand for improved healthcare are some of the major factors. Furthermore, the presence of high unmet clinical needs with regard to treatment issue is the factor propelling the expansion of this vertical. This modality of treatment is expected to gain popularity in the coming years as generic provides better medication compliance.

Get Registered for more detail